<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Di S</submitter><funding>Xingang Cui, Xiuwu Pan,  Sishun Gan, Jian Chu, Qiwei Yang</funding><funding>Xingang Cui, Xiuwu Pan, Sishun Gan, Jian Chu, Qiwei Yang</funding><pagination>186</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10468907</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Renal cell carcinoma (RCC) is a hypermetabolic disease. Abnormal up-regulation of glycolytic signaling promotes tumor growth, and glycolytic metabolism is closely related to immunotherapy of renal cancer. The aim of the present study was to determine whether and how the glycolysis-related biomarker TCIRG1 affects aerobic glycolysis, the tumor microenvironment (TME) and malignant progression of clear cell renal cell carcinoma (ccRCC).&lt;h4>Methods&lt;/h4>Based on The Cancer Genome Atlas (TCGA, n = 533) and the glycolysis-related gene set from MSigDB, we identified the glycolysis-related gene TCIRG1 by bioinformatics analysis, analyzed its immunological properties in ccRCC and observed how it affected the biological function and glycolytic metabolism using online databases such</pubmed_abstract><journal>Cancer cell international</journal><pubmed_title>Glycolysis-related biomarker TCIRG1 participates in regulation of renal cell carcinoma progression and tumor immune microenvironment by affecting aerobic glycolysis and AKT/mTOR signaling pathway.</pubmed_title><pmcid>PMC10468907</pmcid><funding_grant_id>No. 81974391, 82072806, 82173265,82002664；2022LJ002；23QC1401400；23ZR1441300；20204Y0042；21XHDB06; No. 2020-QN-02</funding_grant_id><pubmed_authors>Pan X</pubmed_authors><pubmed_authors>Qian C</pubmed_authors><pubmed_authors>Cui X</pubmed_authors><pubmed_authors>Zhou W</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Sun Y</pubmed_authors><pubmed_authors>Shi X</pubmed_authors><pubmed_authors>Lv J</pubmed_authors><pubmed_authors>Gan S</pubmed_authors><pubmed_authors>Dong K</pubmed_authors><pubmed_authors>Tian Y</pubmed_authors><pubmed_authors>Di S</pubmed_authors><pubmed_authors>Chen W</pubmed_authors><pubmed_authors>Gong M</pubmed_authors><pubmed_authors>Yang Q</pubmed_authors><pubmed_authors>Chu J</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Glycolysis-related biomarker TCIRG1 participates in regulation of renal cell carcinoma progression and tumor immune microenvironment by affecting aerobic glycolysis and AKT/mTOR signaling pathway.</name><description>&lt;h4>Background&lt;/h4>Renal cell carcinoma (RCC) is a hypermetabolic disease. Abnormal up-regulation of glycolytic signaling promotes tumor growth, and glycolytic metabolism is closely related to immunotherapy of renal cancer. The aim of the present study was to determine whether and how the glycolysis-related biomarker TCIRG1 affects aerobic glycolysis, the tumor microenvironment (TME) and malignant progression of clear cell renal cell carcinoma (ccRCC).&lt;h4>Methods&lt;/h4>Based on The Cancer Genome Atlas (TCGA, n = 533) and the glycolysis-related gene set from MSigDB, we identified the glycolysis-related gene TCIRG1 by bioinformatics analysis, analyzed its immunological properties in ccRCC and observed how it affected the biological function and glycolytic metabolism using online databases such</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Aug</publication><modification>2026-07-14T18:36:42.967Z</modification><creation>2025-02-19T04:23:05.197Z</creation></dates><accession>S-EPMC10468907</accession><cross_references><pubmed>37649034</pubmed><doi>10.1186/s12935-023-03019-0</doi></cross_references></HashMap>